TARA
MaterialsProtara Therapeutics Inc
$5.66+0.25 (+4.62%)PRE
Live · NASDAQ · May 8, Close
AI Insight
What's Moving TARA Today?
No stock-specific AI insight has been generated for TARA yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$312M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume577K
Avg Volume (10D)—
Shares Outstanding55.1M
TARA News
20 articles- One Protara Therapeutics Insider Raised Their Stake In The Previous YearYahoo Finance·May 4, 2026
- Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual MeetingYahoo Finance·Apr 27, 2026
- Protara Therapeutics: Q4 Earnings SnapshotYahoo Finance·Mar 10, 2026
- Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business UpdateYahoo Finance·Mar 10, 2026
- Protara Therapeutics Highlights TARA-002 NMIBC Data, FDA Plans for Lymphatic Malformations at Oppenheimer ConfMarketbeat·Mar 2, 2026
- Protara Therapeutics Highlights Phase 2 TARA-002 Data in NMIBC, Cites Strong Response Rates at ASCO GUMarketbeat·Feb 25, 2026
- TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder CancerYahoo Finance·Feb 23, 2026
- Protara Therapeutics to Participate in Upcoming Investor ConferencesYahoo Finance·Feb 19, 2026
- Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Feb 2, 2026
- Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers SymposiumYahoo Finance·Jan 22, 2026
- Protara Therapeutics Highlights Recent Updates and Anticipated 2026 MilestonesYahoo Finance·Jan 12, 2026
- Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceYahoo Finance·Jan 7, 2026
- Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral SupportYahoo Finance·Jan 7, 2026
- Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic MalformationsYahoo Finance·Jan 5, 2026
- Protara Announces Closing of $75 Million Public OfferingYahoo Finance·Dec 8, 2025
- Protara Announces Pricing of $75 Million Public OfferingYahoo Finance·Dec 5, 2025
- Protara Announces Proposed Public OfferingYahoo Finance·Dec 4, 2025
- Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC PatientsYahoo Finance·Dec 3, 2025
- Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025Yahoo Finance·Dec 1, 2025
- Insiders Buying Protara Therapeutics Might Wish They Invested More, Stock Gains 30%Yahoo Finance·Nov 24, 2025
All 20 articles loaded
Price Data
Open$5.45
Previous Close$5.41
Day High$5.68
Day Low$5.41
52 Week High—
52 Week Low—
Fundamentals
Market Cap$312M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume577K
Avg Volume (10D)—
Shares Outstanding55.1M
About Protara Therapeutics Inc
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
MaterialsBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SICBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
CIK—
Composite FIGI—
Share Class FIGI—